Skip to main content
Top
Published in: International Journal of Hematology 3/2004

01-10-2004

Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin’s Lymphomas: Results of a Japanese Phase II Study

Authors: Michinori Ogura, Yasuo Morishima, Yukio Kobayashi, Naokuni Uike, Susumu Sugai, Takaaki Chou, Masaharu Kasai, Ikuo Miura, Tohru Murayama, Yoshihiro Matsuno, Shigeo Nakamura, Shigeo Mori, Yasuo Ohashi, Kensei Tobinai, Members of the Cladribine Study Group

Published in: International Journal of Hematology | Issue 3/2004

Login to get access
Metadata
Title
Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin’s Lymphomas: Results of a Japanese Phase II Study
Authors
Michinori Ogura
Yasuo Morishima
Yukio Kobayashi
Naokuni Uike
Susumu Sugai
Takaaki Chou
Masaharu Kasai
Ikuo Miura
Tohru Murayama
Yoshihiro Matsuno
Shigeo Nakamura
Shigeo Mori
Yasuo Ohashi
Kensei Tobinai
Members of the Cladribine Study Group
Publication date
01-10-2004
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2004
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.04077

Other articles of this Issue 3/2004

International Journal of Hematology 3/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine